Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
Patrik Roser, Franz X. Vollenweider, Wolfram Kawohl
The World Journal of Biological Psychiatry March 1, 2010 DOI: 10.3109/15622970801908047 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Cannabis CBD |
| Keywords | Cannabinoid receptor Pharmacology Endocannabinoid system Antipsychotic Neuroprotection Partial agonist Schizophrenia object-oriented programming |
| Citations | 63 |
| Key findings | Cannabidiol and SR141716 may have antipsychotic properties similar to atypical antipsychotic drugs, supported by experimental studies in animals, healthy volunteers, and schizophrenic patients. |
Abstract
Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the principal psychoactive constituent of the Cannabis sativa plant, and other agonists at the central cannabinoid (CB(1)) receptor may induce characteristic psychomotor effects, psychotic reactions and cognitive impairment resembling schizophrenia. These effects of Delta(9)-THC can be reduced in animal and human models of psychopathology by two exogenous cannabinoids, cannabidiol (CBD) and SR141716. CBD is the second most abundant constituent of Cannabis sativa that has weak partial antagonistic properties at the CB(1) receptor. CBD inhibits the reuptake and hydrolysis of anandamide, the most important endogenous CB(1) receptor agonist, and exhibits neuroprotective antioxidant activity. SR141716 is a potent and selective CB(1) receptor antagonist. Since both CBD and SR141716 can reverse many of the biochemical, physiological and behavioural effects of CB(1) receptor agonists, it has been proposed that both CBD and SR141716 have antipsychotic properties. Various experimental studies in animals, healthy human volunteers, and schizophrenic patients support this notion. Moreover, recent studies suggest that cannabinoids such as CBD and SR141716 have a pharmacological profile similar to that of atypical antipsychotic drugs. In this review, both preclinical and clinical studies investigating the potential antipsychotic effects of both CBD and SR141716 are presented together with the possible underlying mechanisms of action.
Comparable studies
Other narrative reviews on CBD, most cited first.
Citations in the library
Cited by 7
- Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain Frontiers in Pharmacology 2014
- Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research Frontiers in Pharmacology June 21, 2017
- Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis Psychopharmacology January 26, 2021
- Psychotropic Effects of Cannabis Plant-Based Therapeutics, Volume 1 2023
- Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neuroscience Letters May 27, 2011
and 2 more in the library
Cites 20
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers Archives of General Psychiatry December 1, 2000
- Psychiatric effects of cannabis The British Journal of Psychiatry February 1, 2001
- The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval Neuropsychopharmacology February 14, 2007
- Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research Pharmacopsychiatry July 1, 1998
and 15 more in the library